BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 20557351)

  • 1. Activation of the PI3K/AKT signalling pathway in non-melanoma skin cancer is not mediated by oncogenic PIK3CA and AKT1 hotspot mutations.
    Hafner C; Landthaler M; Vogt T
    Exp Dermatol; 2010 Aug; 19(8):e222-7. PubMed ID: 20557351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
    Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
    BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
    Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S
    Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hotspot mutations of PIK3CA and AKT1 genes are absent in multiple myeloma.
    Ismail SI; Mahmoud IS; Msallam MM; Sughayer MA
    Leuk Res; 2010 Jun; 34(6):824-6. PubMed ID: 20022634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women.
    Deng L; Chen J; Zhong XR; Luo T; Wang YP; Huang HF; Yin LJ; Qiu Y; Bu H; Lv Q; Zheng H
    PLoS One; 2015; 10(3):e0120511. PubMed ID: 25816324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
    Trigka EA; Levidou G; Saetta AA; Chatziandreou I; Tomos P; Thalassinos N; Anastasiou N; Spartalis E; Kavantzas N; Patsouris E; Korkolopoulou P
    Oncol Rep; 2013 Aug; 30(2):623-36. PubMed ID: 23728071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathologic and molecular significance of phospho-Akt expression in early invasive breast cancer.
    Aleskandarany MA; Rakha EA; Ahmed MA; Powe DG; Ellis IO; Green AR
    Breast Cancer Res Treat; 2011 Jun; 127(2):407-16. PubMed ID: 20617378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of PIK3CA and Akt/protein kinase B in head and neck squamous cell carcinoma.
    Fenic I; Steger K; Gruber C; Arens C; Woenckhaus J
    Oncol Rep; 2007 Jul; 18(1):253-9. PubMed ID: 17549376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants.
    Hechtman JF; Sadowska J; Huse JT; Borsu L; Yaeger R; Shia J; Vakiani E; Ladanyi M; Arcila ME
    Mol Cancer Res; 2015 Jun; 13(6):1003-8. PubMed ID: 25714871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PIK3CA-AKT pathway mutations in micropapillary breast carcinoma.
    Flatley E; Ang D; Warrick A; Beadling C; Corless CL; Troxell ML
    Hum Pathol; 2013 Jul; 44(7):1320-7. PubMed ID: 23352210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mucinous breast carcinomas lack PIK3CA and AKT1 mutations.
    Kehr EL; Jorns JM; Ang D; Warrick A; Neff T; Degnin M; Lewis R; Beadling C; Corless CL; Troxell ML
    Hum Pathol; 2012 Dec; 43(12):2207-12. PubMed ID: 22705004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of RUNX3 in skin cancers.
    Lee JH; Pyon JK; Kim DW; Lee SH; Nam HS; Kang SG; Kim CH; Lee YJ; Chun JS; Cho MK
    Clin Exp Dermatol; 2011 Oct; 36(7):769-74. PubMed ID: 21623876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations of the PIK3CA gene in diffuse large B cell lymphoma.
    Baohua Y; Xiaoyan Z; Tiecheng Z; Tao Q; Daren S
    Diagn Mol Pathol; 2008 Sep; 17(3):159-65. PubMed ID: 18382359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PIK3CA mutation is associated with a favorable prognosis among patients with curatively resected esophageal squamous cell carcinoma.
    Shigaki H; Baba Y; Watanabe M; Murata A; Ishimoto T; Iwatsuki M; Iwagami S; Nosho K; Baba H
    Clin Cancer Res; 2013 May; 19(9):2451-9. PubMed ID: 23532889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of LKB1 on the PI3K/Akt pathway activation in association with PTEN and PIK3CA in HNC.
    Ekizoglu S; Dogan S; Ulker D; Seven D; Gozen ED; Karaman E; Buyru N
    Clin Otolaryngol; 2015 Dec; 40(6):622-8. PubMed ID: 25850957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AKT1(E17K) in human solid tumours.
    Bleeker FE; Felicioni L; Buttitta F; Lamba S; Cardone L; Rodolfo M; Scarpa A; Leenstra S; Frattini M; Barbareschi M; Grammastro MD; Sciarrotta MG; Zanon C; Marchetti A; Bardelli A
    Oncogene; 2008 Sep; 27(42):5648-50. PubMed ID: 18504432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of COX-2 activity and CRP levels in patients with non-melanoma skin cancer. -765G>C PTGS2 polymorphism and NMSC risk.
    Cocoş R; Schipor S; Nicolae I; Thomescu C; Raicu F
    Arch Dermatol Res; 2012 Jul; 304(5):335-42. PubMed ID: 22159575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specific gene expression signatures induced by the multiple oncogenic alterations that occur within the PTEN/PI3K/AKT pathway in lung cancer.
    De Marco C; Laudanna C; Rinaldo N; Oliveira DM; Ravo M; Weisz A; Ceccarelli M; Caira E; Rizzuto A; Zoppoli P; Malanga D; Viglietto G
    PLoS One; 2017; 12(6):e0178865. PubMed ID: 28662101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma.
    Rahman M; Nakayama K; Rahman MT; Nakayama N; Ishikawa M; Katagiri A; Iida K; Nakayama S; Otsuki Y; Shih IeM; Miyazaki K
    Hum Pathol; 2012 Dec; 43(12):2197-206. PubMed ID: 22705003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical galectin-3 expression in non-melanoma skin cancers.
    Kapucuoglu N; Basak PY; Bircan S; Sert S; Akkaya VB
    Pathol Res Pract; 2009; 205(2):97-103. PubMed ID: 18951731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.